Cannabidiol (CBD) has been scientifically shown to be effective in the treatment of certain epilepsies, pain, inflammation and nausea, as well as providing relief from hangover, anxiety and stress.
Cannabidiol (CBD) has been scientifically shown to be effective in the treatment of certain epilepsies, pain, inflammation and nausea, as well as providing relief from hangover, anxiety and stress.
With the North American cannabis market boasting an estimated worth of $7.2 billion in 2016, and new reports projecting CAGR of between 17 percent and 25 percent within the next few years, it’s certainly an exciting time to invest in the marijuana market.
ChineseInvestors.com, Inc. (OTCQB: CIIX), a company in the business of providing Chinese-speaking investors with real-time market analysis, commentary, and educational services, recently announced its goals for 2017, stating that it plans to develop a CBD oil-based pharmaceutical that could help with the major problem of epilepsy in China.
Now, India Globalization Capital, Inc. (NYSE MKT: IGC) is taking a leaf from the Sony playbook. This pioneering company is a ‘first mover’ in the cannabinoid combination therapy space.
One of the very first licensed producers and a pioneer in Canadian medical cannabis, ABcann Global Corporation (TSX.V: ABCN) (OTCQB: ABCCF) has always held to meticulous specifications in the production of its pharmaceutical grade, plant-based medicines.
The cannabis industry has swiftly turned into a multi-billion dollar opportunity. In the United States, this market’s massive growth potential is being recognized as new states legalize marijuana for medical or recreational use.
Growing marijuana in North America, for obvious reasons, has historically been an underground affair. Amid growing legalization in favor of recreational and medicinal use, growing cannabis on mass scale is rapidly becoming a necessity for companies in a burgeoning industry driven by incredible consumer demand.
Cannabis has been used for thousands of years as a form of natural remedy. But, over time, the possession of marijuana was made illegal in many countries, until now.
CBD has long been considered to have a broad range of medical benefits. Now, two major studies released in the last four months have scientifically validated the medicinal efficacy of CBD.
According to the study, patients who received CBD treatment exhibited over 45 percent mean reduction in seizures, and researchers were outspoken in support of further research.
Cannabis is now legal medically or recreationally in 28 states in the U.S., and companies such as India Globalization Capital, Inc. (NYSE MKT: IGC) are developing revolutionary cannabinoid-based combination pharmaceutical therapies.
India Globalization Capital (NYSE MKT: IGC), an innovator in developing cannabis-based combination therapies to treat pain and other conditions, is currently applying the revolutionary seizure-treating potential of CBD to another population: domestic pets, and the company is addressing the 5 percent of dogs and just over 2 percent of cats in the United States that experience seizures.
Bitcoin’s recent climb above the $4,500 mark is just one example of how its market capitalization continues to gain unprecedented reach. (http://nnw.fm/lGp8V) From cannabis to technology, bitcoin has impacted industries far and wide, but analysts believe that the cryptocurrency isn’t done climbing.
The backbone of medical advancement is biotechnology, an industry wrought with the incredible potential of novel drug R&D, but vulnerable to the risk of stringent regulatory approval processes. Within this volatile market, however, is the cannabis-biotech sub-sector – a market flourishing with opportunity, innovation, and deep roots of medical possibilities.
On Monday, January 30, 2017, Alan Klitenic, the Director of Investor Relations for ChineseInvestors.com, Inc. (OTCQB: CIIX), was interviewed by NetworkNewsWire.